Cargando…

TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan()

BACKGROUND: This study examined usefulness and efficiency of Lurasidone in appraisal with the placebo as for the treatment of Bipolar Disorders. METHODS: Seven treatment centers in Pakistan were selected for the purpose of starting a six week-long control trial (randomized and double-blind placebo)....

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Nasar, Nasar, Amina, Bajwa, Saqib, Jawad Butt, Aisha, Azher, Afia, Mushtaq, Tehmina, Rashid, Alina, Haq, Mian Mukhtar Ul, Rasul, Ghulam, Dogar, Firasat Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783817/
https://www.ncbi.nlm.nih.gov/pubmed/33424407
http://dx.doi.org/10.1016/j.sjbs.2020.11.044
_version_ 1783632176904929280
author Khan, Nasar
Nasar, Amina
Bajwa, Saqib
Jawad Butt, Aisha
Azher, Afia
Mushtaq, Tehmina
Rashid, Alina
Haq, Mian Mukhtar Ul
Rasul, Ghulam
Dogar, Firasat Ali
author_facet Khan, Nasar
Nasar, Amina
Bajwa, Saqib
Jawad Butt, Aisha
Azher, Afia
Mushtaq, Tehmina
Rashid, Alina
Haq, Mian Mukhtar Ul
Rasul, Ghulam
Dogar, Firasat Ali
author_sort Khan, Nasar
collection PubMed
description BACKGROUND: This study examined usefulness and efficiency of Lurasidone in appraisal with the placebo as for the treatment of Bipolar Disorders. METHODS: Seven treatment centers in Pakistan were selected for the purpose of starting a six week-long control trial (randomized and double-blind placebo). 76 subjects, already diagnosed with Bipolar I or II based on DSM 5 diagnosis, were selected after randomization. Patients were allocated in one of the two groups. Primary efficacy of the drug was measured using Young Mania Rating Scale. Positive response of the drug was defined as 50% reduction in symptoms from the baseline/13 point less than the baseline score on Young Mania Rating Scale. Efficacy and safety of the drug was assessed using variety of markers such as administering extra-pyramidal symptoms rating scale, adverse side effects reported, electrocardiograms, body weight, vital signs changes, and laboratory investigations. RESULTS: Patients treated with Lurasidone showed enhanced improvement in their overall health and symptoms manifestation in comparison to patients who were given placebo. Lurasidone treated patients showed a better response to the drug (66%), in comparison with the placebo treated patients (42%). LIMITATIONS: Study was conducted on small scale due to complexity. CONCLUSION: Patients treated with Lurasidone showed reduction in bipolar symptoms and tolerate the drug well.
format Online
Article
Text
id pubmed-7783817
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-77838172021-01-08 TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan() Khan, Nasar Nasar, Amina Bajwa, Saqib Jawad Butt, Aisha Azher, Afia Mushtaq, Tehmina Rashid, Alina Haq, Mian Mukhtar Ul Rasul, Ghulam Dogar, Firasat Ali Saudi J Biol Sci Original Article BACKGROUND: This study examined usefulness and efficiency of Lurasidone in appraisal with the placebo as for the treatment of Bipolar Disorders. METHODS: Seven treatment centers in Pakistan were selected for the purpose of starting a six week-long control trial (randomized and double-blind placebo). 76 subjects, already diagnosed with Bipolar I or II based on DSM 5 diagnosis, were selected after randomization. Patients were allocated in one of the two groups. Primary efficacy of the drug was measured using Young Mania Rating Scale. Positive response of the drug was defined as 50% reduction in symptoms from the baseline/13 point less than the baseline score on Young Mania Rating Scale. Efficacy and safety of the drug was assessed using variety of markers such as administering extra-pyramidal symptoms rating scale, adverse side effects reported, electrocardiograms, body weight, vital signs changes, and laboratory investigations. RESULTS: Patients treated with Lurasidone showed enhanced improvement in their overall health and symptoms manifestation in comparison to patients who were given placebo. Lurasidone treated patients showed a better response to the drug (66%), in comparison with the placebo treated patients (42%). LIMITATIONS: Study was conducted on small scale due to complexity. CONCLUSION: Patients treated with Lurasidone showed reduction in bipolar symptoms and tolerate the drug well. Elsevier 2021-01 2020-11-24 /pmc/articles/PMC7783817/ /pubmed/33424407 http://dx.doi.org/10.1016/j.sjbs.2020.11.044 Text en Crown Copyright © 2020 Published by Elsevier B.V. on behalf of King Saud University. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Khan, Nasar
Nasar, Amina
Bajwa, Saqib
Jawad Butt, Aisha
Azher, Afia
Mushtaq, Tehmina
Rashid, Alina
Haq, Mian Mukhtar Ul
Rasul, Ghulam
Dogar, Firasat Ali
TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan()
title TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan()
title_full TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan()
title_fullStr TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan()
title_full_unstemmed TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan()
title_short TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan()
title_sort tulip study: trail of lurasidone in bipolar disorder in pakistan()
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783817/
https://www.ncbi.nlm.nih.gov/pubmed/33424407
http://dx.doi.org/10.1016/j.sjbs.2020.11.044
work_keys_str_mv AT khannasar tulipstudytrailoflurasidoneinbipolardisorderinpakistan
AT nasaramina tulipstudytrailoflurasidoneinbipolardisorderinpakistan
AT bajwasaqib tulipstudytrailoflurasidoneinbipolardisorderinpakistan
AT jawadbuttaisha tulipstudytrailoflurasidoneinbipolardisorderinpakistan
AT azherafia tulipstudytrailoflurasidoneinbipolardisorderinpakistan
AT mushtaqtehmina tulipstudytrailoflurasidoneinbipolardisorderinpakistan
AT rashidalina tulipstudytrailoflurasidoneinbipolardisorderinpakistan
AT haqmianmukhtarul tulipstudytrailoflurasidoneinbipolardisorderinpakistan
AT rasulghulam tulipstudytrailoflurasidoneinbipolardisorderinpakistan
AT dogarfirasatali tulipstudytrailoflurasidoneinbipolardisorderinpakistan